Spots Global Cancer Trial Database for A Study of Relatlimab in Combination With Nivolumab in Participants With Advanced Liver Cancer Who Have Never Been Treated With Immuno-oncology Therapy After Prior Treatment With Tyrosine Kinase Inhibitors
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: A Study of Relatlimab in Combination With Nivolumab in Participants With Advanced Liver Cancer Who Have Never Been Treated With Immuno-oncology Therapy After Prior Treatment With Tyrosine Kinase Inhibitors
Official Title: A Phase 2, Randomized, Open-label Study of Relatlimab in Combination With Nivolumab in Participants With Advanced Hepatocellular Carcinoma Who Are Naive to IO Therapy But Progressed on Tyrosine Kinase Inhibitors (RELATIVITY-073)
Study ID: NCT04567615
Study Description
Brief Summary: The purpose of this study is to evaluate the effectiveness and safety of relatlimab in combination with nivolumab in participants with advanced liver cancer who have never been treated with immuno-oncology therapy, after prior treatment with tyrosine kinase inhibitor therapy.
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Local Institution - 0010, Ciudad de Buenos Aires, Buenos Aires, Argentina
Local Institution - 0019, Buenos Aires, Distrito Federal, Argentina
Local Institution - 0017, Rosario, Santa Fe, Argentina
Local Institution - 0063, San Miguel de Tucumán, Tucuman, Argentina
Local Institution - 0025, Belo Horizonte, Minas Gerais, Brazil
Local Institution - 0060, Porto Alegre, RIO Grande DO SUL, Brazil
Fundação Pio XII - Hospital de Câncer de Barretos-Unidade de Pesquisa Clínica, Barretos, SAO Paulo, Brazil
Unidade de Pesquisa Clínica do Hospital da Clínicas de Ribeirão Preto-Clinical Oncology, Ribeirao Preto, SAO Paulo, Brazil
Local Institution - 0015, São Paulo, SAO Paulo, Brazil
Local Institution - 0024, Temuco, Araucanía, Chile
Local Institution - 0029, Santiago, Metropolitana, Chile
Local Institution - 0018, Santiago, Metropolitana, Chile
Local Institution - 0113, Harbin, Heilongjiang, China
Local Institution - 0114, Changsha, Hunan, China
Local Institution - 0118, Xi'an, Shaanxi, China
Local Institution - 0108, Xi'an, Shan3xi, China
Local Institution - 0107, Shanghai, Shanghai, China
Local Institution - 0117, Hangzhou, Zhejiang, China
Local Institution - 0048, Brno, , Czechia
Local Institution - 0047, Hradec Kralove, , Czechia
Local Institution - 0046, Prague, , Czechia
Local Institution - 0069, Vandoeuvre lès Nancy, Meurthe-et-Moselle, France
Local Institution - 0068, Clichy, , France
Local Institution - 0105, Grenoble, , France
Local Institution - 0074, Lyon, , France
Local Institution - 0067, Pessac, , France
Local Institution - 0077, Hksar, , Hong Kong
Local Institution - 0079, Shatin, , Hong Kong
Local Institution - 0072, Matsuyama, Ehime, Japan
Local Institution - 0054, Yokohama, Kanagawa, Japan
Local Institution - 0076, Yokohama, Kanagawa, Japan
Local Institution - 0045, Osaka-sayama, Osaka, Japan
Local Institution - 0075, Ishikawa, , Japan
Local Institution - 0071, Kyoto, , Japan
Local Institution - 0011, Seoul, Seoul-teukbyeolsi, Korea, Republic of
Local Institution - 0020, Seongnam-si, , Korea, Republic of
Local Institution - 0043, Seoul, , Korea, Republic of
Local Institution - 0101, San Luis Potosí, SAN LUIS Potosi, Mexico
Local Institution - 0100, Cuauhtémoc, , Mexico
Local Institution - 0106, Oaxaca, , Mexico
Local Institution - 0003, Auckland, , New Zealand
Local Institution - 0013, Krakow, Małopolskie, Poland
Local Institution - 0012, Bytom, , Poland
Local Institution - 0009, Mysowice, , Poland
Local Institution - 0039, Warszawa, , Poland
Local Institution - 0037, București, , Romania
Local Institution - 0036, Cluj, , Romania
Local Institution - 0038, Craiova, , Romania
Local Institution - 0070, Suceava, , Romania
Local Institution - 0001, Singapore, Central Singapore, Singapore
Local Institution - 0004, Singapore, , Singapore
Local Institution - 0050, San Sebastian, Gipuzkoa, Spain
Local Institution - 0066, Barcelona, , Spain
Local Institution - 0073, Cordoba, , Spain
Local Institution - 0051, Madrid, , Spain
Local Institution - 0049, Madrid, , Spain
Local Institution - 0058, Pamplona, , Spain
Local Institution - 0041, Taichung, , Taiwan
Local Institution - 0034, Tainan, , Taiwan
Local Institution - 0031, Taipei City, , Taiwan
Local Institution - 0042, Taipei, , Taiwan
Local Institution - 0032, Taoyuan, , Taiwan
Local Institution - 0089, Ankara, , Turkey
Local Institution - 0090, Edirne, , Turkey
Local Institution - 0091, Kadiköy/Istanbul, , Turkey
Contact Details
Name: Bristol-Myers Squibb
Affiliation: Bristol-Myers Squibb
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
